In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.
Vous n'êtes pas connecté
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio
In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.
Bayer (BAYRY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this...
Bayer (BAYRY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this...
Based on the average brokerage recommendation (ABR), Sony (SONY) should be added to one's portfolio. Wall Street analysts' overly optimistic...
Based on the average brokerage recommendation (ABR), GE Vernova (GEV) should be added to one's portfolio. Wall Street analysts' overly optimistic...
TUESDAY, March 25, 2025 -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new...
TUESDAY, March 25, 2025 -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new...
Based on the average brokerage recommendation (ABR), Grab (GRAB) should be added to one's portfolio. Wall Street analysts' overly optimistic...
BAYRY suffers a setback after the jury at the Barnes Roundup trial in the State Court of Cobb County, Georgia, reached a verdict in favor of the...
Mohamed El-Shimy, Minister of Public Enterprises, and Ali El-Ghamrawy, Chairperson of the Egyptian Drug Authority (EDA), conducted an extensive field...